Search
EHA joins ESMO in calling for EU action on shortages of essential medicines
EHA joins ESMO in calling for EU action on shortages of essential medicines
The European Hematology Association (EHA) has endorsed and signed a collective Call to Action, prepared by the European Society for Medical Oncology (ESMO), on shortages of inexpensive, essential…
Hematology in the spotlight at EAPM Presidency Conference
April 9, Brussels - The European Alliance for Personalised Medicine is holding its 7th annual presidency conference at the University Foundation in Brussels, and the event will include a session on Hematology - Personalised treatment and personalised prevention.
Read moreMission ‘Gene Therapy’ for Horizon Europe
Mission ‘Gene Therapy’ for Horizon Europe
Advanced therapies, such as gene therapy, hold promise for treating a wide range of chronic diseases and improving patients’ quality of life.
“Who dares wins,” - Elizabeth Macintyre, woman in hematology/EHA volunteer
Elizabeth Macintyre is currently EHA Board Secretary. She got her MD/PhD is Britain, her PhD in France and post-doc in America.
Read moreUptake of CAR T cell therapy in Europe
Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.
Read moreHealth Technology Assessment (HTA)
Every European citizen should have access to the best quality medical care at the best possible price. Pan-European cooperation on health technology assessments (HTA) is essential for such aspirations.
Read moreGAPP Joint Action
Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.
Read moreMeet Fabienne Lucas, our January Volunteer of the Month
EHA is a Public Benefit Organization under Dutch law.
Read moreMeet Fabienne Lucas, our January Volunteer of the Month
EHA is a Public Benefit Organization under Dutch law.
Read moreFirst CMML guidelines produced by EHA, now available
Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- »